Metastatic Prostate Cancer: Symptoms, Diagnosis & Treatment

Metastatic Prostate Cancer Guide: Diagnosis, Treatment & Care

How does metastatic prostate cancer spread?

Metastatic cancer has a few main pathways it can travel. Understanding these can help patients and families prepare for the challenges ahead.

• •Bones:
  The most common site, often leading to pain or fractures.
• •Lymph nodes:
  Cancer cells spread through the body’s drainage system.
• •Liver:
  Less common, but can signal advanced metastatic prostate cancer.
• •Lungs:
  May occur in aggressive cases, indicating widespread disease.

So, in essence: aggressive = speed and behaviour; advanced = extent and stage.

Symptoms of metastatic prostate cancer

• •Bone pain:
  The most common symptom, often felt in the hips, back, or ribs.
• •Fatigue:
  Ongoing tiredness that doesn’t improve with rest.
• •Urinary symptoms:
  Difficulty urinating, weak flow, or frequent nighttime trips.
• •Systemic signs:
  weight loss, loss of appetite, or general weakness may signal wider disease.

Diagnosis of metastatic prostate cancer

When facing this diagnosis, it helps to know what to expect. Oncologists usually move step by step:

• •Looking at symptoms and Exam
  Oncologists usually begin by asking about metastatic prostate cancer symptoms - things like bone pain, fatigue, or urinary changes. They may also do a digital rectal exam, where the doctor gently feels the prostate through the rectum to check for lumps or irregularities.
• •Checking PSA levels in the blood
  Next comes the PSA test. PSA stands for prostate-specific antigen, a protein made by the prostate. High PSA levels in the blood can signal prostate cancer or that it has started to spread.
• •Confirming with a biopsy
  To be sure, a biopsy is done. This involves taking tiny tissue samples from the prostate. A pathologist studies these under a microscope and assigns a “Gleason score” or “Grade Group,” which tells doctors how aggressive the cancer cells look.
• •Imaging to confirm and stage spread
  Once cancer is confirmed, oncologists use imaging to see how far it has gone. Bone scan for skeletal involvement. CT scan for lymph nodes and organs. MRI for local detail and spine/bone clarity. PSMA PET for high-sensitivity whole-body staging.
• •Multidisciplinary Plan
  Results are combined to stage disease and select the best metastatic prostate cancer treatment options for the patient. This ensures timely, tailored care before starting treatment.

Staging and classification of metastatic spread of prostate cancer

Staging explains the extent of the cancer, and classification explains its nature. Below is a simple breakdown that combines both:

Confused about the terms above? Here's the breakdown:

Get Your Free Cancer Diet Plan & Report Analysis Now on WhatsApp

Talk to experts. Understand your reports. Get a personalized diet plan — all free to start.

Get My Free Plan on WhatsApp

India's First Cancer Care Management Platform

Free to start•Secure & private•No app download needed

• •T / T1, T2, T3, T4:
  “T” is tumour extent. T1 = very small, hidden; T2 = confined but detectable; T3 = spread beyond prostate; T4 = into nearby organs.
• •N / N0, N1:
  Whether cancer is in regional lymph nodes (N1) or not (N0).
• •M / M0, M1:
  Distant spread. M1 = metastasis to bones, organs, etc.

Metastatic prostate cancer treatment options

Treatment options for this type of cancer are rarely a one-size-fits-all approach. Oncologists combine multiple of them based on how advanced the cancer is and each patient’s overall health.

• •Hormone therapy (androgen deprivation therapy)
  Most metastatic prostate cancer treatment guidelines begin with hormone therapy. The goal is to lower testosterone levels, since prostate cancer cells often need this hormone to grow. This is usually the first line when it comes to controlling the growth of the disease.
• •Chemotherapy for advanced cases
  When cancer becomes resistant to hormone therapy or is very aggressive, chemotherapy is introduced. Drugs like docetaxel or cabazitaxel help slow disease progression and improve survival.
• •Targeted therapy and immunotherapy
  Newer metastatic prostate cancer treatments include targeted therapies such as PARP inhibitors (for men with certain gene mutations). As well as immunotherapy drugs that activate the body’s immune system. These are often used in more aggressive tumours.
• •Radiation therapy and radiopharmaceuticals
  For men with painful bone metastases, radiation helps relieve symptoms. Newer radiopharmaceuticals like radium-223 target cancer in the bones directly, improving both comfort and outcomes in the final stages of metastatic prostate cancer.
• •Surgery in select situations
  While less common in metastatic cases, surgery (like prostatectomy) may still be considered in limited disease or as part of combination therapy. It’s often discussed within metastatic prostate cancer treatment guidelines as a case-by-case option.
• •Clinical trials and emerging therapies
  For patients seeking cutting-edge care, clinical trials offer access to the latest treatment options. These may include next-generation hormone drugs, novel radiotherapies, or precision medicine approaches.
• •Supportive and palliative care
  Beyond active treatment, supportive care is key in the management of this cancer. This includes pain control, bone-strengthening medicines, mental health support, and improving daily quality of life.

Metastatic prostate cancer survival rates and prognosis

While every patient’s journey is different, studies provide averages that help explain outcomes. Here are the typical survival rates for metastatic prostate cancer:

• •Stage I–II
  > 99%
• •Stage III
  > 99%
• •Stage IV
  37%
• •All stages combined
  97%

While men with localised or regional disease often live as long as those without cancer, survival in advanced cases is much lower.

Still, it’s important to remember these are averages. Factors like tumour aggressiveness, PSA levels, and how well someone responds to the treatments strongly affect prognosis.

Stay informed about metastatic prostate cancer